95 related articles for article (PubMed ID: 6275568)
1. A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin.
Saldeen T; Ryan JW; Berryer P
Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):465-70. PubMed ID: 6275568
[No Abstract] [Full Text] [Related]
2. [Changes of depressor responses to bradykinin with preparations blocking kininase and adrenoreceptors].
Gomazkov OA; Shimkovich MV
Kardiologiia; 1974 Jul; 14(7):57-66. PubMed ID: 4154383
[No Abstract] [Full Text] [Related]
3. Effect of a fibrin-derived vasoactive peptide on pulmonary angiotensin converting enzyme activity and on pressure responses to bradykinin.
Moalli R; Saldeen K; Saldeen T
J Pharmacol Exp Ther; 1987 Dec; 243(3):897-900. PubMed ID: 3694536
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
5. The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme.
Hayashi MA; Murbach AF; Ianzer D; Portaro FC; Prezoto BC; Fernandes BL; Silveira PF; Silva CA; Pires RS; Britto LR; Dive V; Camargo AC
J Neurochem; 2003 May; 85(4):969-77. PubMed ID: 12716428
[TBL] [Abstract][Full Text] [Related]
6. Comparison of blood pressure responses to intra-arterial and intra-venous injections of angiotensin I, angiotensin II and bradykinin.
Heller LJ; Mohrman DE
Life Sci; 1998; 62(9):PL121-5. PubMed ID: 9496705
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats.
Paula RD; Lima CV; Khosla MC; Santos RA
Hypertension; 1995 Dec; 26(6 Pt 2):1154-9. PubMed ID: 7498987
[TBL] [Abstract][Full Text] [Related]
8. Lung peptidases, including carboxypeptidase, modulate airway reactivity to intravenous bradykinin.
Chodimella V; Skidgel RA; Krowiak EJ; Murlas CG
Am Rev Respir Dis; 1991 Oct; 144(4):869-74. PubMed ID: 1928964
[TBL] [Abstract][Full Text] [Related]
9. Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme.
Collier JG; Robinson BF; Vane JR
Lancet; 1973 Jan; 1(7794):72-4. PubMed ID: 4118651
[No Abstract] [Full Text] [Related]
10. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of a new bradykinin potentiating octapeptide from gamma-casein.
Lebrun I; Lebrun FL; Henriques OB; Carmona AK; Juliano L; Camargo AC
Can J Physiol Pharmacol; 1995 Jan; 73(1):85-91. PubMed ID: 7600458
[TBL] [Abstract][Full Text] [Related]
12. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
13. SQ 14,225 (D-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme.
Rubin B; Laffan RJ; Kotler DG; O'Keefe EH; Demaio DA; Goldberg ME
J Pharmacol Exp Ther; 1978 Feb; 204(2):271-80. PubMed ID: 202692
[No Abstract] [Full Text] [Related]
14. Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I.
Häckl LP; Cuttle G; Dovichi SS; Lima-Landman MT; Nicolau M
Pharmacology; 2002 Aug; 65(4):182-6. PubMed ID: 12174832
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin I converting enzyme and kininase in rabbit plasma by bradykinin potentiating peptide B (Pyr-Gly-Leu-Pro-Arg-Pro-Lys-Ile-Pro-Pro).
Ueda E; Kokubu T; Akutsu H; Yamamura Y
Experientia; 1971 Sep; 27(9):1020-1. PubMed ID: 4329994
[No Abstract] [Full Text] [Related]
16. Biologically active peptides from Bothrops jararacussu venom.
Ferreira LA; Henriques OB; Lebrun I; Batista MB; Prezoto BC; Andreoni AS; Zelnik R; Habermehl G
Agents Actions Suppl; 1992; 36():209-14. PubMed ID: 1609644
[TBL] [Abstract][Full Text] [Related]
17. A study of some bradykinin potentiating peptides derived from plasma proteins.
Faber DB; Van der Meer C
Arch Int Pharmacodyn Ther; 1973 Oct; 205(2):226-43. PubMed ID: 4358297
[No Abstract] [Full Text] [Related]
18. Measurement of des-Phe8-Arg9-bradykinin by enzyme-immunoassay--a useful parameter of plasma kinin release.
Majima M; Ueno A; Sunahara N; Katori M
Adv Exp Med Biol; 1989; 247B():331-5. PubMed ID: 2692413
[No Abstract] [Full Text] [Related]
19. [Relationship between the kininase- and angiotensin- converting activity under normal conditions and in experimental myocardial infarct].
Gomazkov OA; Shimkovich MV; Chernukh AM
Kardiologiia; 1977 Jan; 17(1):103-8. PubMed ID: 192936
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.
Arbin V; Claperon N; Fournié-Zaluski MC; Roques BP; Peyroux J
Br J Pharmacol; 2000 Jul; 130(6):1297-304. PubMed ID: 10903969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
